Assertio Therapeutics (NASDAQ: ASRT) reported Q2 EPS of $0.28, $0.20 better than the analyst estimate of $0.08. Revenue for the quarter came in at $35.4 million versus the consensus estimate of $31.63 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.